Oclacitinib (BioDeep_00000858972)
代谢物信息卡片
化学式: C15H23N5O2S (337.1572)
中文名称: 奥拉替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CNS(=O)(=O)CC1CCC(CC1)N(C)C2=NC=NC3=C2C=CN3
InChI: InChI=1S/C15H23N5O2S/c1-16-23(21,22)9-11-3-5-12(6-4-11)20(2)15-13-7-8-17-14(13)18-10-19-15/h7-8,10-12,16H,3-6,9H2,1-2H3,(H,17,18,19)
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Jun-Jie Qin, Hao Zhu, Zhe-Wen Song, Xiao-Jiao Hou, Xiu-Min Wang, Lei Wang, Jian-Xi Li. A randomized double-blind clinical trial: Comparison of oclacitinib with a traditional Chinese herbal medicine product (Dihuang Guiqin capsule) in the treatment of canine atopic dermatitis.
Research in veterinary science.
2024 May; 171(?):105221. doi:
10.1016/j.rvsc.2024.105221. [PMID: 38490043] - Laszlo Hunyadi, Palika Datta, Kathleen Rewers-Felkins, Emily Sundman, Thomas Hale, Virginia Fajt, Sarah Wagner. Pharmacokinetics of a single dose of oclacitinib maleate as a top dress in adult horses.
Journal of veterinary pharmacology and therapeutics.
2022 May; 45(3):320-324. doi:
10.1111/jvp.13043. [PMID: 35098559] - Junko Takahashi, Satoko Kanda, Ichiro Imanishi, Tadashi Hisano, Teruyasu Fukamachi, Norihito Taguchi, Shoko Momiyama, Satoshi Nishiyama, Tomoki Motegi, Keita Iyori. Efficacy and safety of 0.0584\% hydrocortisone aceponate topical spray and systemic oclacitinib combination therapy in dogs with atopic dermatitis: a randomized, double-blinded, placebo-controlled trial.
Veterinary dermatology.
2021 Apr; 32(2):119-e25. doi:
10.1111/vde.12909. [PMID: 33185330] - Lluís Ferrer, Isaac Carrasco, Carles Cristòfol, Anna Puigdemont. A pharmacokinetic study of oclacitinib maleate in six cats.
Veterinary dermatology.
2020 Apr; 31(2):134-137. doi:
10.1111/vde.12819. [PMID: 31769185] - Natália Lôres Lopes, Diefrey Ribeiro Campos, Marília Alves Machado, Mariana Silva Revoredo Alves, Manuela Silva Gomes de Souza, Cristiano Chaves Pessoa da Veiga, Alexandre Merlo, Fábio Barbour Scott, Julio Israel Fernandes. A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats.
BMC veterinary research.
2019 May; 15(1):137. doi:
10.1186/s12917-019-1893-x. [PMID: 31068210] - Chiara Noli, Irina Matricoti, Carlo Schievano. A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood-induced hypersensitivity dermatitis.
Veterinary dermatology.
2019 Apr; 30(2):110-e30. doi:
10.1111/vde.12720. [PMID: 30656750] - Andrew C Simpson, Jennifer R Schissler, Rod A W Rosychuk, A Russell Moore. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.
Veterinary dermatology.
2017 Oct; 28(5):485-e113. doi:
10.1111/vde.12450. [PMID: 28513001] - Andrea J Gonzales, Timothy J Fleck, William R Humphrey, Betsy A Galvan, Michelle M Aleo, Sean P Mahabir, Jezaniah-Kira Tena, Karen G Greenwood, Robert B McCall. IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics.
Veterinary dermatology.
2016 Feb; 27(1):34-e10. doi:
10.1111/vde.12280. [PMID: 26666963] - Sallie B Cosgrove, Dawn M Cleaver, Vickie L King, Amy R Gilmer, Anne E Daniels, Jody A Wren, Michael R Stegemann. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life.
Veterinary dermatology.
2015 Jun; 26(3):171-9, e35. doi:
10.1111/vde.12194. [PMID: 25688708] - W T Collard, B D Hummel, A F Fielder, V L King, J F Boucher, M A Mullins, P B Malpas, M R Stegemann. The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog.
Journal of veterinary pharmacology and therapeutics.
2014 Jun; 37(3):279-85. doi:
10.1111/jvp.12087. [PMID: 24330031]
